Epiphany Begins Valomaciclovir Study

Epiphany Biosciences has started a Phase II trial with valomaciclovir for acute infectious mononucleosis.

Brian Murphy, Epiphany’s chief medical officer, said the double-blind, placebo-controlled trial will examine fluctuations in viral load as influenced by valomaciclovir and assess symptom scores.

The study will mark the first of several studies of valomaciclovir against Epstein-Barr virus-related diseases.